Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rabeprazole sodium Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Rabeprazole Protection of Aspirin Induced Gastric Damage.

NCT00220857
View directory record Official record
Conditions
Normal Subjects
Interventions
Rabeprazole
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2008 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797
View directory record Official record
Conditions
Infectious Disease
Interventions
Acalabrutinib, Rabeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects

NCT04211545
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Rabeprazole, CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib Food Effect and Proton Pump Inhibitor Study

NCT04645940
View directory record Official record
Conditions
Drug Interaction, Food-drug Interaction
Interventions
fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

NCT02097329
View directory record Official record
Conditions
Healthy
Interventions
palbociclib commercial free base, famotidine, rabeprazole, antacid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

NCT01398046
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Dasatinib plus Rabeprazole, Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

NCT01237353
View directory record Official record
Conditions
Pharmacodynamic
Interventions
betaine hydrochloride, Rabeprazole
Dietary Supplement · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 3, 2026, 9:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928
View directory record Official record
Conditions
Healthy Adults, Healthy
Interventions
PF-08049820, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

NCT01287091
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

NCT00199953
View directory record Official record
Conditions
Postnasal Drainage
Interventions
Rabeprazole 20 mg twice a day for 90-day period treatment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 3, 2026, 9:38 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

NCT06916143
View directory record Official record
Conditions
Healthy Participants
Interventions
LY4100511, Rabeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

NCT05330858
View directory record Official record
Conditions
Pharmacokinetics
Interventions
ESK-001, Rabeprazole
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

NCT00287391
View directory record Official record
Conditions
Insomnia, GERD
Interventions
Rabeprazole
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2007 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986365, Rabeprazole
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 16 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Surufatinib DDI With a PPI and a CYP3A Inducer

NCT04510649
View directory record Official record
Conditions
Healthy
Interventions
Part A, Part B
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants

NCT07329972
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

NCT05602597
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg, Rabeprazole 40 mg
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 2 Interventional

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170
View directory record Official record
Conditions
Esophageal Reflux
Interventions
Rabeprazole
Drug
Lead sponsor
University of Kansas
Other
Eligibility
19 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658528
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 3, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT01918176
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 3, 2026, 9:38 AM EDT